期刊文献+

肿瘤型M2丙酮酸激酶在乳腺癌中表达的意义及其临床应用价值 被引量:3

The expression and value of tumor type M2 pyruvate kinase in the diagnosis of breast cancer
下载PDF
导出
摘要 目的:探讨肿瘤型M2丙酮酸激酶(TuM2-PK)在乳腺癌患者血中的表达水平及其临床应用价值。方法:用ELISA法分别检测52例乳腺癌、36例乳腺良性病变患者和60名健康体检者血浆中的TuM2-PK表达水平,并进行比较分析。结果:TuM2-PK在乳腺癌组阳性率为76.92%,乳腺良性病变组为16.67%,健康对照组为20.00%,乳腺癌组明显高于后两组(P<0.01),有淋巴结转移患者TuM2-PK阳性率(81.25%)高于无淋巴结转移患者(45.00%)(P<0.05)。结论:TuM2-PK对乳腺癌的辅助诊断有较高的临床价值,并对判断淋巴结转移及临床治疗具有一定的指导意义。 Objective: To investigate the expression and diagnostic values of tumor M2-PK(TuM2-PK) in breast cancer.Methods: The concentration of tumor M2-PK in plasma was detected by ELISA in 52 patients with breast cancer,36 patients with breast benign disease and 60 health controls.Results: TuM2-PK concentration in plasma and the positive rate were singificanfly higher in breast cancer(76.92%) than that in breast benign disease and in health controls(16.67% and 20.00%,respectively)(P〈0.01),TuM2-PK levels was higher in breast cancer patients with lymph node metastasis(81.25%) than that without metastasis(45.00%)(P〈0.05).Conclusion: The measurement of TuM2-PK is of great clinical value for the diagnosis of breast cancer,and is helpful in the evaluation of lymph node metastasis.
出处 《中国医药导报》 CAS 2010年第35期22-23,共2页 China Medical Herald
关键词 乳腺肿瘤 肿瘤标志物 丙酮酸激酶 Breast neoplasm Tumor marker Pyruvate kinase
  • 相关文献

参考文献11

  • 1胡志东,王金良.一种新的肿瘤标志物TU M2-PK的研究进展[J].国外医学(临床生物化学与检验学分册),2005,26(3):162-164. 被引量:15
  • 2吴健民.影响肿瘤标志物检测的因素[J].中华检验医学杂志,2005,28(4):352-354. 被引量:22
  • 3Eigenbrodt E,Reinacher M,Scheefers-Borchel U,et al.Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells[J].Crit Rev Oncog,1992,3(1-2):91-115.
  • 4Hugo F,Fischer G,Eigenbrodt E.Quantitative detection of tumor M2-PK in serum and plasma[J].Anticancer Res,1999,19(4A):2753-2757.
  • 5Eigenbrodt E,Basenau D,Holthusen S,et al.Quantification of tumor type M2 pyruvate kinase (TuM2-PK) in human carcinomas[J].Anticancer Res,1997,17(4B):3153-3156.
  • 6Mazurek S,Boschek CB,Hugo F,et al.Pyruvate kinase type M2 and its role in tumor growth and spreading[J].Semin Cancer Biol,2005,15:300-308.
  • 7Hoopmann M,Warm M,Mallmann I,et al.Tumor M2 pyruvate kinase determination in breast cancer patients receiving trastuzumab therapy[J].Cancer Lett,2002,187(1-2):223-228.
  • 8Luftner D,Mesterharm J,Akrivakis C,et al.Tumor type M2 pyruvate kinase expression in advanced breast cancer[J].Anticancer Res,2000,20(6D):5077-5082.
  • 9Schneider J,Peltri G,Bitterlich N,et al.Fuzzy logic-based tumor marker profiles including a new marker Tumor M2-PK improved sensitivity to the detection of progression in lung cancer patietts[J].Anticancer Res,2003,23(2A):899-906.
  • 10Luftner D,Mesterhann J,Akrivakis C,et al.Tumor type M2 pyruvate kinase expression in advanced breast cancer[J].Anticancer Res,2000,20(6D):5077-5082.

二级参考文献42

  • 1Mazlurek S,Bosckhek CB,Hugo F,et al. Pgrubate Kinase type M2 and its role in tumor growth and spreeding[J]. Sen in Cancer Biol, 2005,15 (4) : 300-308.
  • 2Mazurek S,Zwerschke W,Jansen-DarrP,et al. Metabolie cooperation between different oncogenes during cell transfor- mation:interaction berween activated vas and Hpv-16 ET [ J ]. Oncogene, 2001,20(47 ) :6891-6898.
  • 3Mazurek S,Grimm H,Oehmke M,et al. Tumor M2-PK and glutam imolytic enzymes in the metabolic shift of tumor tells [J ]. Anticancer Res, 2000,20(6D ) : 5151-5154.
  • 4Mazure R S,Grimm H,Boschek CB,et al. Pyruvate kinase type M2:a crossroad im the tumor metabolome[J]. Br J Nutr,2002,87(Suppl 1 ) :23-29.
  • 5Hugo F,Fischer G, Eigenbrodt E. Quantilative deiection dejection of tumor M2-PK,in serum, and Plasma [J]. Anticacer Res, 1999,19(4) : 2753.
  • 6Lufiner D,Mesterharm J,Akrivakis C,et al. Tumor type M2 pyruvate Kinase expression in advanced breast cancer[J]. Anticaner Res, 2000,20( 6D ) : 5077-5082.
  • 7Schneider J,Neu K,Veleorsky H G,et al. Tumor M2- pyruvate kinase in the follow-up of inoperable lung cancer patients : a pilot study [ J ]. Cancer Lett, 2003,193 ( 1 ) : 91-98.
  • 8Schneider J, Veleovsky H G, Morr H, et al. Comparison of the tumor markers tumor M2-PK, CEA, CYERA21- 1, NSE and SCC in the diagnosis of lung cancer[J]. Anticancer Res, 2000,20(6D) : 5053-5058.
  • 9Hudelist G,Kostler W,Czerw enka K,et al. Predicting the clinical course of brest cancer patients undergoing trastummab-based therapy:an outlook[J]. Methods Find Exp Clin Pharmacol, 2004,26 ( 3 ) : 201-210.
  • 10Schneider J,Elitterlich N,Schulze G. Improved sensitivity in the diagnosis of gastro-intertinal tumors by fuzzy logicbased tumor maker profiles including the tumor M2-PK [ J ]. Anticancer Res, 2005,25 ( 3A ) : 1507-1515.

共引文献37

同被引文献42

  • 1张新,周志祥.TUM_2-PK、NSE、CEA和CYFRA21-1联合检测对肺癌诊断的临床价值[J].航空航天医学杂志,2009,21(11):31-33. 被引量:1
  • 2丁志祥,解东涯,杨春秀,秦建萍.血浆TU M_2-PK检测对肺癌的诊断价值[J].第二军医大学学报,2006,27(2):219-220. 被引量:6
  • 3王东,周娟,刘敏,徐鸿绪.肿瘤型M2丙酮酸激酶在肺癌诊断中的应用[J].中华检验医学杂志,2007,30(5):541-543. 被引量:5
  • 4梁道源,姚桂琴.肿瘤型丙酮酸激酶与消化系统肿瘤的研究[J].医学综述,2007,13(13):984-985. 被引量:2
  • 5Ewald N,Schaller M,Bayer M,et al. Fecal pyruvate kinase-M2(tumorM2-PK) measurement:a new screening concept for colorectal cancer. Anticancer Res,2007,27:1949-1952.
  • 6Kumar Y,Tapuria N,Kimani N,et al. Tumor M2-pyiuvate kinase a gastrointestinal cancer marke. Eur J Gastroen-terol Hepatol,2007,19:265-267.
  • 7Spoden GA,Mazurek S,Morandell D,et al. Isotype-specific inhibitors of the glycolytic key regulator pyruvate kinase subtype M2 moderately decelerate tumor cell proliferation. Int J Cancer,2008,123:312-321.
  • 8Mazurek S. Pyruvate kinase type M2:a key regulator within the tumour metabolo me and a tool for metabolic p rofilling of tumours. Ernst Schering Found Symp Proc,2007,4:99-124.
  • 9Oremek G,Kukshalte R,Sapoutzis N,et al. The significance of TU M2-PK tumor marker for lung cancer diagnostics. Klin Med (Mosk),2007,85:56-58.
  • 10Jemal A,Siegel R,Xu J,et al. Cancer statistics,2010 [J]. CA Cancer J Clin, 2010,60(5 ) : 277-300.

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部